WO2004043435A3 - Systemic delivery of antiviral agents - Google Patents

Systemic delivery of antiviral agents Download PDF

Info

Publication number
WO2004043435A3
WO2004043435A3 PCT/US2003/036637 US0336637W WO2004043435A3 WO 2004043435 A3 WO2004043435 A3 WO 2004043435A3 US 0336637 W US0336637 W US 0336637W WO 2004043435 A3 WO2004043435 A3 WO 2004043435A3
Authority
WO
WIPO (PCT)
Prior art keywords
agent
risk
treating
reducing
antiviral agents
Prior art date
Application number
PCT/US2003/036637
Other languages
French (fr)
Other versions
WO2004043435A2 (en
Inventor
Paul Ashton
Jianbing Chen
Thomas J Smith
Original Assignee
Control Delivery Sys Inc
Paul Ashton
Jianbing Chen
Thomas J Smith
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Control Delivery Sys Inc, Paul Ashton, Jianbing Chen, Thomas J Smith filed Critical Control Delivery Sys Inc
Priority to AU2003287666A priority Critical patent/AU2003287666A1/en
Publication of WO2004043435A2 publication Critical patent/WO2004043435A2/en
Publication of WO2004043435A3 publication Critical patent/WO2004043435A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The systems and methods disclosed herein provide sustained delivery of a therapeutic agent for treating a patient, e.g., human, to obtain a desired local or systemic physiological or pharmacological effect. Method includes positioning the sustained released drug delivery system at an area wherein release of the agent is desired and allowing the agent to pass through the device to the desired area of treatment. In some embodiments, the method is for treating or reducing the risk of retroviral or lentiviral infection. In certain embodiments, the method is for preventing or reducing the risk of mother-to-child transmission of HIV, wherein the therapeutic agent is an antiviral agent.
PCT/US2003/036637 2002-11-13 2003-11-13 Systemic delivery of antiviral agents WO2004043435A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003287666A AU2003287666A1 (en) 2002-11-13 2003-11-13 Systemic delivery of antiviral agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42594302P 2002-11-13 2002-11-13
US60/425,943 2002-11-13

Publications (2)

Publication Number Publication Date
WO2004043435A2 WO2004043435A2 (en) 2004-05-27
WO2004043435A3 true WO2004043435A3 (en) 2004-07-08

Family

ID=32313080

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/036637 WO2004043435A2 (en) 2002-11-13 2003-11-13 Systemic delivery of antiviral agents

Country Status (2)

Country Link
AU (1) AU2003287666A1 (en)
WO (1) WO2004043435A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
DK2155169T3 (en) 2007-06-08 2016-06-13 Boehringer Ingelheim Int Formulation of nevirapine extended release
AU2010249683B2 (en) * 2009-05-18 2015-06-25 Dose Medical Corporation Drug eluting ocular implant
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
EP2515864A4 (en) * 2009-12-23 2013-09-11 Psivida Inc Sustained release delivery devices
AR088463A1 (en) 2011-10-21 2014-06-11 Abbvie Inc METHODS FOR HCV TREATMENT
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
TWI532485B (en) 2011-10-21 2016-05-11 艾伯維有限公司 Methods for treating hcv
US10517759B2 (en) 2013-03-15 2019-12-31 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
KR20170016884A (en) * 2014-05-30 2017-02-14 텍스타일-베이스드 딜리버리, 인코포레이티드 Drug delivery systems and related methods of use
WO2016069898A1 (en) 2014-10-30 2016-05-06 Textile-Based Delivery, Inc. Delivery systems
WO2017040853A1 (en) 2015-09-02 2017-03-09 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
EP3442479A1 (en) 2016-04-20 2019-02-20 Harold Alexander Heitzmann Bioresorbable ocular drug delivery device
EP3448392A4 (en) 2016-04-28 2020-01-15 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5902598A (en) * 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
US6039975A (en) * 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US6039975A (en) * 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
US5902598A (en) * 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices

Also Published As

Publication number Publication date
WO2004043435A2 (en) 2004-05-27
AU2003287666A1 (en) 2004-06-03
AU2003287666A8 (en) 2004-06-03

Similar Documents

Publication Publication Date Title
WO2004043435A3 (en) Systemic delivery of antiviral agents
WO2001080825A3 (en) Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
WO2004091444A3 (en) Implantable medical device comprising therapeutic agents with different diffusion rates
NO20034684D0 (en) Device for administering funds through the stratum corcum
WO2004010975A3 (en) Controlled drug delivery
WO2003077972A8 (en) Implantable drug delivery system
NO962833L (en) Transdermal preparation comprising polyvinylpyrrolidine
WO2004062600A3 (en) Antiviral patch
WO2008086375A3 (en) Non-invasive vascular treatment systems, devices, and methods of using the same
NO20051964D0 (en) Therapeutic preparations for drug delivery to and through the epithelium
WO2006036982A3 (en) Drug delivery coating for use with a stent
DE60136910D1 (en) DEVICE WITH ENERGY CONVERSION DEVICES FOR IMPOTENA TREATMENT
WO2005079387A3 (en) Implantable drug delivery device including wire filaments
WO2003028660A3 (en) Drug delivery devices and methods
WO2000038714A8 (en) The prevention and treatment of retinal ischemia and edema
DK1133269T3 (en) Controlled delivery device for administration of therapeutics in the inner ear
WO2001043749A3 (en) Pharmaceutical implant containing immediate-release and sustained-release components and method of administration
WO2007030478A3 (en) Implantable device for therapeutic treatment within a body lumen
CA2401000A1 (en) Method of treating and diagnosing sleep disordered breathing and means for carrying out the method
AU3401093A (en) Therapeutic agent for threatened abortion
CY1106702T1 (en) USE OF A COMBINATION OF A PURINE AND A NITROGEN MONOXIDE DONATOR FOR THE PREVENTION OR TREATMENT OF BENEFITS OF BENEFITS
WO2001041771A3 (en) Transdermal system containing acetylsalicylic acid for treatment of migraine
AR109456A2 (en) USE OF ET743 FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF A HUMAN PATIENT AFFECTED BY CANCER THROUGH COMBINATION THERAPY
WO2002007760A3 (en) Therapeutic agent against aids comprising anti hiv goat antibody
James New double vs. triple antiviral combination study, CD4 200-500, no prior treatment

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP